GrowingWithAK
← Back

LIC Mutual Fund · #152024

LIC MF Healthcare Fund - Direct Plan - Growth

Equity · Sectoral/ Thematic · Direct · Growth

Direct TER: 1.38% · as of

5-year NAV · change the window using the controls in the rolling-returns card below ↓

2023-07-31 → 2026-10-22

min ₹19.66 change +70.9% max ₹38.28

Latest NAV

₹34.6303

as of 2026-10-22 · +0.02% vs 2026-10-21

Earliest NAV in archive

2023-07-31

AMFI archive begins Apr 2006

Worst peak-to-trough drawdown

-15.10%

trough 2025-02-28 (since archive start)

Trailing CAGR vs assigned benchmark

Window Scheme CAGR Benchmark CAGR Excess Period
1y +4.95% — — 2025-10-23 → today · 1.0y
3y +20.50% — — 2023-10-23 → today · 3.0y

Benchmark assignment is mapped by category and sub-category from public sources. "Since inception (in archive)" uses the earliest NAV in the AMFI archive (April 2006 onward).

Rolling 1-year returns distribution · 551 daily entry points · last 5 years

Imagine buying this fund on any day in this period and holding for exactly one year. Each bar counts how often that ended with a given return: green bars made money, red bars lost money even after a full year. Taller bar = more common outcome.

0% -5.6% to -3.3%: 11 windows -3.3% to -1.0%: 35 windows -1.0% to +1.4%: 43 windows +1.4% to +3.7%: 38 windows +3.7% to +6.0%: 25 windows +6.0% to +8.3%: 26 windows +8.3% to +10.6%: 33 windows +10.6% to +12.9%: 46 windows +12.9% to +15.3%: 32 windows +15.3% to +17.6%: 52 windows +17.6% to +19.9%: 58 windows +19.9% to +22.2%: 11 windows +22.2% to +24.5%: 8 windows +24.5% to +26.9%: 4 windows +26.9% to +29.2%: 5 windows +29.2% to +31.5%: 2 windows +31.5% to +33.8%: 6 windows +33.8% to +36.1%: 4 windows +36.1% to +38.4%: 0 windows +38.4% to +40.8%: 6 windows +40.8% to +43.1%: 6 windows +43.1% to +45.4%: 12 windows +45.4% to +47.7%: 13 windows +47.7% to +50.0%: 16 windows +50.0% to +52.4%: 9 windows +52.4% to +54.7%: 6 windows +54.7% to +57.0%: 18 windows +57.0% to +59.3%: 8 windows +59.3% to +61.6%: 11 windows +61.6% to +63.9%: 7 windows -6% +64%

Median 1y return

+14.5%

Mean 1y return

+18.8%

Best / worst 1y

+63.9% / -5.6%

Windows positive

88%

5th %ile -2.3%
25th %ile +4.8%
75th %ile +22.6%
95th %ile +56.8%

Beat-benchmark consistency · vs assigned benchmark, across overlapping windows

Of all the rolling windows we observed, how often did this fund's return exceed the benchmark's over the same window. A higher fraction means more consistent outperformance, but says nothing about future windows.

Period Windows beat Total windows % beat Avg excess
(annualised)
1y rolling 375 551 68% +1.8%

Monthly returns · since inception (Jul 2023)

How each calendar month went: green months gained, red months lost. Deeper colour = bigger move.

Year Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Year
2026 -5.8 +4.9 -4.6 +7.5 +4.6 +4.0 +4.3 +4.8 -5.2 -5.1 · · +8.4
2025 -6.0 -8.9 +8.8 -0.8 +0.5 +3.4 +3.7 -3.4 -0.0 +2.9 +0.4 -2.6 -3.2
2024 +5.6 +4.1 +1.0 +1.7 -1.5 +4.3 +11.2 +6.1 +2.0 +2.0 +0.3 +0.8 +43.9
2023 · · · · · · · -0.7 +2.5 -3.7 +11.4 +3.7 +13.2
Avg -2.1 +0.0 +1.7 +2.8 +1.2 +3.9 +6.4 +1.7 -0.2 +0.4 +4.0 +0.6 +20.3

All values in %. Each cell compares the last NAV of the month with the last NAV of the month before. The latest month is month-to-date; the Year column compounds the months shown on that row. The Avg row is the plain average of each column across the years shown (2 complete calendar years in the last column); the running month is left out of it.

Portfolio mix · asset class breakdown as of 2026-09-30

Equity 97.5%
Other / unclassified 2.5%
Equity split: Large 30.4% Mid 32.0% Small 35.1%

Size axis (Style Box) · Large / Mid / Small split of latest disclosed holdings

Per AMFI's semi-annual Categorisation of Stocks (top 100 = Large, 101-250 = Mid, 251+ = Small).

  • Large Cap 30.4%
  • Mid Cap 32.0%
  • Small Cap 35.1%
  • Cash & Equivalents 2.5%

Index overlap

· vs · share of this fund's AUM that sits in stocks the index also includes

No holdings data yet for this fund.

Top stocks held · 25 holdings as of 2026-09-30 See changes vs previous snapshot →

Stock Sector % of fund
Sun Pharmaceutical Industries Ltd. Pharmaceuticals & Biotechnology 9.59%
Divi's Laboratories Ltd. Pharmaceuticals & Biotechnology 9.07%
Neuland Laboratories Ltd. Pharmaceuticals & Biotechnology 6.14%
Torrent Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 6.04%
Apollo Hospitals Enterprise Ltd. Healthcare Services 5.75%
Aurobindo Pharma Ltd. Pharmaceuticals & Biotechnology 5.23%
Navin Fluorine International Ltd. Chemicals & Petrochemicals 4.98%
Zydus Lifesciences Ltd. Pharmaceuticals & Biotechnology 4.97%
Aster DM Quality Care Ltd. Healthcare Services 4.61%
Fortis Healthcare Ltd. Healthcare Services 3.77%
Metropolis Healthcare Ltd. Healthcare Services 3.35%
Gland Pharma Ltd. Pharmaceuticals & Biotechnology 3.20%
Mankind Pharma Ltd. Pharmaceuticals & Biotechnology 3.11%
Nephrocare Health Services Ltd. Healthcare Services 3.05%
Max Healthcare Institute Ltd. Healthcare Services 2.99%
Cohance Lifesciences Ltd. Pharmaceuticals & Biotechnology 2.95%
Glenmark Pharmaceuticals Ltd. Pharmaceuticals & Biotechnology 2.61%
Global Health Ltd. Healthcare Services 2.59%
Dr Agarwal's Health Care Ltd. Healthcare Services 2.46%
Biocon Ltd. Pharmaceuticals & Biotechnology 2.37%

Sector mix

Healthcare: 94.9% Chemicals: 5.1%
  • Healthcare 94.9%
  • Chemicals 5.1%

Risk metrics, trailing 3y (734 matched daily returns, 2023-10-25 → 2026-10-22)

Sharpe

+1.00

excess return per unit of total volatility

Sortino

+1.39

excess return per unit of downside vol

Calmar

+1.36

CAGR / |max DD| in window

Beta vs benchmark

+0.86

scheme sensitivity to benchmark moves

Tracking error

+6.50%

annualised stdev of (scheme − benchmark)

Up capture

+87.1%

% of benchmark gain captured on up days

Down capture

+81.8%

% of benchmark loss participated in

Risk-free rate assumed 6.0% annualised. Benchmark = Nifty Healthcare Index (assigned by category mapping).

Factual data only. No investment advice or recommendation. Read the scheme document and consult a SEBI-registered Investment Adviser for personalised guidance.